ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

ClinicalTrials.gov ID: NCT00652925

Public ClinicalTrials.gov record NCT00652925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

Study identification

NCT ID
NCT00652925
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
225 participants

Conditions and interventions

Interventions

  • Celecoxib Drug
  • Naproxen Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2002
Primary completion
Mar 31, 2004
Completion
Mar 31, 2005
Last update posted
May 29, 2008

2002 – 2005

United States locations

U.S. sites
31
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site Hartford Connecticut 06106
Pfizer Investigational Site Delray Beach Florida 33484
Pfizer Investigational Site Miami Florida 33155
Pfizer Investigational Site St. Petersburg Florida 33701
Pfizer Investigational Site Chicago Illinois 60614
Pfizer Investigational Site Chicago Illinois 60637
Pfizer Investigational Site Chicago Illinois 60649
Pfizer Investigational Site Glenview Illinois 60025
Pfizer Investigational Site Hinsdale Illinois 60521
Pfizer Investigational Site Merrillville Indiana 46410
Pfizer Investigational Site New Orleans Louisiana 70118
Pfizer Investigational Site Boston Massachusetts 02115
Pfizer Investigational Site Worcester Massachusetts 01610
Pfizer Investigational Site Omaha Nebraska 68178
Pfizer Investigational Site Livingston New Jersey 07039
Pfizer Investigational Site New Hyde Park New York 11040
Pfizer Investigational Site New York New York 10032
Pfizer Investigational Site Tulsa Oklahoma 74133
Pfizer Investigational Site Tulsa Oklahoma 74135
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Portland Oregon 97227-1623
Pfizer Investigational Site Portland Oregon 97232
Pfizer Investigational Site Altoona Pennsylvania 16601
Pfizer Investigational Site Altoona Pennsylvania 16602
Pfizer Investigational Site Duncansville Pennsylvania 16635
Pfizer Investigational Site Hershey Pennsylvania 17033
Pfizer Investigational Site Johnstown Pennsylvania 15904
Pfizer Investigational Site Lancaster Pennsylvania 17604
Pfizer Investigational Site Milwaukee Wisconsin 53201
Pfizer Investigational Site Milwaukee Wisconsin 53226-0509

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00652925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 29, 2008 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00652925 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →